Production (Stage)
Acurx Pharmaceuticals, Inc.
ACXP
$0.473
-$0.026-5.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -21.57% | 1.93% | 37.89% | 36.37% | 28.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.03% | -3.26% | 29.18% | 27.22% | 30.24% |
| Operating Income | 26.03% | 3.26% | -29.18% | -27.22% | -30.24% |
| Income Before Tax | 26.03% | 3.26% | -29.18% | -27.22% | -30.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 26.03% | 3.26% | -29.18% | -27.22% | -30.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.03% | 3.26% | -29.18% | -27.22% | -30.24% |
| EBIT | 26.03% | 3.26% | -29.18% | -27.22% | -30.24% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 40.02% | 22.87% | -3.13% | -1.93% | -6.47% |
| Normalized Basic EPS | 40.03% | 22.88% | -3.13% | -1.94% | -6.48% |
| EPS Diluted | 40.02% | 22.87% | -3.13% | -1.93% | -6.47% |
| Normalized Diluted EPS | 40.03% | 22.88% | -3.13% | -1.94% | -6.48% |
| Average Basic Shares Outstanding | 26.88% | 27.47% | 26.96% | 24.81% | 22.04% |
| Average Diluted Shares Outstanding | 26.88% | 27.47% | 26.96% | 24.81% | 22.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |